Podcast

Matching Treatment Options to the Patient: The Role of Botulinum Toxin in Pediatric Patients with Spasticity

Launch Date
06/11/2020
Credit Amount
0.00 Expired
Credit Expires
06/11/2022

Faculty

David M. Simpson, MD, FAAN
Professor of Neurology, Icahn School of Medicine at Mount Sinai, New York, NY
Director, Clinical Neurophysiology and Neuromuscular Division, Icahn School of Medicine at Mount Sinai, New York, NY
David M. Simpson, MD, FAAN

David M. Simpson, MD, is Professor of Neurology at Icahn School of Medicine at Mount Sinai in New York, New York. He is also Director of the Clinical Neurophysiology Laboratories and Neuromuscular Division.

Dr. Simpson received his medical degree from State University of New York (SUNY) at Buffalo School of Medicine. He completed an internship in Internal Medicine at University Hospitals of Cleveland, Case Western Reserve University in Cleveland, Ohio, and a residency in Neurology at Cornell University Medical Center in New York. He had a fellowship in Clinical Neurophysiology at Massachusetts General Hospital, Harvard Medical School, in Boston, Massachusetts.

Dr. Simpson is author of over 246 original peer-reviewed publications, 96 book chapters and, has edited 3 books, and serves on numerous editorial boards. He has been the principal investigator for numerous studies, including the treatment of neuropathic pain in patients with peripheral neuropathy, neurological complications of HIV/AIDS and treatment of spasticity, limb dystonia and tremor with botulinum toxin. He is Chair of the American Academy of Neurology’s Subcommittee charged with generating evidence-based guidelines for the use of botulinum toxin. Dr. Simpson is a member of the American Neurological Association and the American Pain Society, Fellow of the American Academy of Neurology and the American Academy of Neuromuscular and Electrodiagnostic Medicine and President-Elect of the International Neurotoxin Association. He has received the Mitchell B Max Award for Neuropathic Pain from the American Academy of Neurology in 2018, granted for outstanding achievements in the field of neuropathic pain.

Explore By Section
Statement of Need Learning Objectives Financial Support Target Audience Credit Information Disclosure Declaration Additional Formats

Statement of Need

Spasticity, a motor disorder characterized by a velocity-dependent increase in tonic stretch reflexes with exaggerated tendon jerks, results from hyper excitability of the stretch reflex. It often causes damage to one or more areas of the central nervous system; therefore, treatment goals should aim to provide symptom relief, ease patient care and decrease caregiver burden, and improve patient function. In order to accomplish these goals, it is imperative that clinicians develop individualized treatment strategies based on shared decision-making, available treatment options, and patient specific factors.

This CMEOCast podcast episode highlights how best to match treatment options with patients, with a specific focus on the safety and efficacy of botulinum toxin as a treatment for patients with spasticity.

Learning Objectives

At the end of this CME/CE activity, participants should be able to:

  • Recognize the clinical manifestations of spasticity.
  • Develop individualized treatment strategies based on shared goals, available treatment options and patient-specific factors.

The following learning objectives pertain only to those requesting CNE or CPE credit:

  • Recognize the clinical manifestations of spasticity.
  • Describe individualized treatment strategies based on shared goals, available treatment options and patient-specific factors.

Financial Support

Supported by an educational grant from Allergan.

Target Audience

Physicians, PAs, nurse practitioners, and pharmacists.

Credit Information

Physicians (ACCME)

CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. CME Outfitters, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacists/Pharmacy Tech (ACPE)

This application-based activity is approved for 1.0 contact hour (0.10 CEUs) of continuing pharmacy credit.

ABIM MOC

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC point in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

ABPN MOC

ABPN Diplomates may select any CME activity relevant to their practice to count towards ABPN MOC requirements.

Royal College MOC

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

MIPS Improvement Activity

This activity counts towards MIPS Improvement Activity requirements under the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

Note to Nurse Practitioners

Nurse Practitioners can apply for AMA PRA Category 1 Credit ™ through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit ™ from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.

Disclosure Declaration

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. Simpson reports that he receives research/grants from Allergan; Ipsen Biopharmaceuticals, Inc.; Merz Pharma; and Revance Therapeutics, Inc. He is on the advisory committee for Allergan; Ipsen Biopharmaceuticals, Inc; Merz Pharma; and Revance Therapeutics, Inc. He is a consultant for Allergan; Ipsen Biopharmaceuticals, Inc.; Merz Pharma; and Revance Therapeutics, Inc. He is on the speakers bureau for Allergan; Ipsen Biopharmaceuticals, Inc.; Merz Pharma; and Revance Therapeutics, Inc.

  • Evan Luberger (planning committee) has no disclosures to report.
  • Jan Perez (planning committee) has no disclosures to report.
  • Sharon Tordoff (planning committee) has no disclosures to report.
  • Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.

Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

Additional Formats

Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit our Privacy & Confidentiality page.

 

NOTE: Pharmacist CE Universal Activity Number, Enduring: 0376-0000-20-100-H01-P.

Questions about this activity?

Call us at 877.CME.PROS (877.263.7767).

 

 

PD-022-061120-03

Related Activities

Diversity & Inclusion
03/22/2023

Health Inequities in Mental Health Care

0.75
Begin Learn More
Neuropsychiatric
05/03/2023

Global Perspectives on Diagnosis and Management of Childhood Epilepsy Disorders

1.00 Hours
Register Learn More
Neuropsychiatric
11/14/2022

Adult Considerations in Spinal Muscular Atrophy: Building Clinician and Patient Medical Teams

1.00 Hours
Begin Learn More
Matching Treatment Options to the Patient: The Role of Botulinum Toxin in Pediatric Patients with Spasticity
Event Date: 06/11/2020
Begin